Correction (DOI:10.1016/j.jvs.2008.11.001);Inhibition of smooth muscle cell migration and neointima formation in vein grafts by overexpression of matrix metalloproteinase-3

Journal of Vascular Surgery

Volumn 49, Issue 3, 2009, Pages 750-758

  Kallenbach, Klaus ^a   Salcher, Rolf ^b   Heim, Albert ^b   Karck, Matthias ^a   Mignatti, Paolo ^c   Haverich, Axel ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; CHOLESTEROL; STROMELYSIN;

ADENOVIRUS; AMNION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL WALL; BYPASS SURGERY; CAROTID ARTERY; CELL MIGRATION; CONTROLLED STUDY; EMBRYO; EX VIVO STUDY; FEMALE; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; JUGULAR VEIN; NEW ZEALAND; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RABBIT; SMOOTH MUSCLE FIBER; STENOSIS; STROMA; VEIN GRAFT; ZYMOGRAPHY;

EID: 61349100922     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2009.03.005     Document Type: Erratum

References (39)

1. Klinkert P., Post P.N., Breslau P.J., and van Bockel J.H. Saphenous vein versus PTFE for above-knee femoropopliteal bypass. A review of the literature. Eur J Vasc Endovasc Surg 27 (2004) 357-362
2. Taylor L.M., Edwards J.M., and Porter J.M. Present status of reversed vein bypass grafting: five-year results of a modern series. J Vasc Surg 11 (1990) 193-206
3. Shah D.M., Darling III C., Chang B.B., Fitzgerald K.M., Paty P.S.K., and Leather R.P. Long-term results of in situ saphenous vein grafts. Analysis of 2058 cases. Ann Surg 222 (1995) 438-448
4. Goldman S., Zadina K., Moritz T., Ovitt T., Sethi G., Copeland J.G., et al., VA Cooperative Study Group #207/297/364. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study. J Am Coll Cardiol 44 (2004) 2149-2156
5. Fitzgibbon G.M., Kafka H.P., Leach A.J., Keon W.J., Hooper G.D., and Burton J.R. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 28 (1996) 616-626
6. Gibbons G.H., and Dzau V.J. The emerging concept of vascular remodeling. N Engl J Med 330 (1994) 1431-1438
7. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1993) 801-809
8. Newby A.C. Dual role of matrix metalloproteinases (matrixins) in intimal hyperplasia and atherosclerosis plaque rupture. Physiol Rev 85 (2005) 1-31
9. Mignatti P., Rifkin D., Welgus H., and Parks W. Proteinases and tissue remodeling. In: Clark R.A.F. (Ed). The molecular and cellular biology of wound repair 14 (1996), Plenum Press, New York 427-474
10. Henney A.M., Wakeley P.R., Davies M.J., Foster K., Hembry R., Murphy G., and Humphries S. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA 88 (1991) 8154-8158
11. Galis Z.S., Sukhova G.K., Lark M.W., and Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94 (1994) 2493-2503
12. Ye S., Eriksson P., Hamsten A., Kurkinen M., Humphries S.E., and Henney A.M. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 271 (1996) 13055-13060
13. Humphries S., Bauters C., Meirhaeghe A., Luong L., Bertrand M., and Amouyel P. The 5A6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene as a risk factor for restenosis. Eur Heart J 23 (2002) 721-725
14. Johnson J.L., George S.J., Newby A.C., and Jackson C.L. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci USA 102 (2005) 15575-15580
15. Terashima M., Akita H., Kanazawa K., Inoue N., Yamada S., Ito K., et al. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation 99 (1999) 2717-2719
16. Kallenbach K., Fernandez H.A., Baumann F.G., Seghezzi G., Patel S., Grossi E.A., et al. A quantitative in vitro model of smooth muscle cell migration through the arterial wall using the human amniotic membrane. Arterioscler Thromb Vasc Biol 23 (2003) 1008-1013
17. Fernandez H.A., Kallenbach K., Seghezzi G., Mehrara B., Apazidis A., Baumann F.G., et al. Modulation of matrix metalloproteinase activity in human saphenous vein grafts using adenovirus-mediated gene transfer. Surgery 124 (1998) 129-136
18. Visse R., and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92 (2003) 827-839
19. Pintucci G., Yu P.J., Sharony R., Baumann F.G., Saponara F., Frasca A., et al. Induction of stromelysin-1 (MMP-3) by fibroblast growth factor-2 (FGF-2) in FGF-2-/-microvascular endothelial cells requires prolonged activation of extracellular signal-regulated kinases-1 and -2 (ERK-1/2). J Cell Biochem 90 (2003) 1015-1025
20. March K.L., Madison J.E., and Trapnell B.C. Pharmacokinetics of adenoviral vector-mediated gene delivery to vascular smooth muscle cells: modulation by poloxamer 407 and implications for cardiovascular gene therapy. Hum Gene Ther 6 (1995) 41-53
21. James T.W., Wagner R., White L.A., Zwolak R.M., and Brinckerhoff C.E. Induction of collagenase and stromelysin gene expression by mechanical injury in a vascular smooth muscle-derived cell line. J Cell Physiol 157 (1993) 426-437
22. Lovdahl C., Thyberg J., Cercek B., Blomgren K., Dimayuga P., Kallin B., et al. Antisense oligonucleotides to stromelysin mRNA inhibit injury-induced proliferation of arterial smooth muscle cells. Histol Histopathol 14 (1999) 1101-1112
23. Gnasso A., Motti C., Irace C., Carallo C., Liberatoscioli L., Bernardini S., et al. Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. Arterioscler Thromb Vasc Biol 20 (2000) 1600-1605
24. Silence J., Lupu F., Collen D., and Lijnen H.R. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol 21 (2001) 1440-1445
25. Turner N.A., Ho S., Warburton P., O'Regan D.J., and Porter K.E. Smooth muscle cells cultured from human saphenous vein exhibit increased proliferation, invasion, and mitogen-activated protein kinase activation in vitro compared with paired internal mammary artery cells. J Vasc Surg 45 (2007) 1022-1028
26. Mekontso-Dessap A., Kirsch M., Guignambert C., Zadigue P., Adnot S., Loisance D., et al. Vascular-wall remodeling of 3 human bypass vessels: organ culture and smooth muscle cell properties. J Thorac Cardiovasc Surg 131 (2006) 651-658
27. Deng D.X., Spin J.M., Tsalenko A., Vailaya A., Ben-Dor A., Yakhini Z., et al. Molecular signatures determining coronary artery and saphenous vein smooth muscle cell phenotypes: distinct responses to stimuli. Arterioscler Thromb Vasc Biol 26 (2006) 1058-1065
28. Davies M.G., and Hagen P.O. Pathophysiology of vein graft failure: a review. Eur J Vasc Endovasc Surg 9 (1995) 7-18
29. Angelini G.D., Bryan A.J., Williams H.M., Soyombo A.A., Williams A., Tovey J., et al. Time-course of medial and intimal thickening in pig venous arterial grafts: relationship to endothelial injury and cholesterol accumulation. J Thorac Cardiovasc Surg 103 (1992) 1093-1103
30. Santos M.F., Viar M.J., McCormack S.A., and Johnson L.R. Polyamines are important for attachment of IEC-6 cells to extracellular matrix. Am J Physiol 273 (1997) G175-G183
31. Everitt E.A., Malik A.B., and Hendey B. Fibronectin enhances the migration rate of human neutrophils in vitro. J Leukoc Biol 60 (1996) 199-206
32. Grotendorst G.R., Seppa H.E., Kleinman H.K., and Martin G.R. Attachment of smooth muscle cells to collagen and their migration toward platelet-derived growth factor. Proc Natl Acad Sci USA 78 (1981) 3669-3672
33. van Hinsbergh V.W., Engelse M.A., and Quax P.H. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol 26 (2006) 716-728
34. Bajou K., Noël A., Gerard R.D., Masson V., Brunner N., Holst-Hansen C., et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4 (1998) 923-928
35. Bajou K., Masson V., Gerard R.D., Schmitt P.M., Albert V., Praus M., et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 152 (2001) 777-784
36. Nishimura T., Nakamura K., Kishioka Y., Kato-Mori Y., Wakamatsu J., and Hattori A. Inhibition of matrix metalloproteinases suppresses the migration of skeletal muscle cells. J Muscle Res Cell Motil 29 (2008) 37-44
37. Haro H., Crawford H.C., Fingleton B., MacDougall J.R., Shinomiya K., Spengler D.M., et al. Matrix metalloproteinase-3-dependent generation of a macrophage chemoattractant in a model of herniated disc resorption. J Clin Invest 105 (2000) 133-141
38. Haro H., Crawford H.C., Fingleton B., Shinomiya K., Spengler D.M., and Matrisian L.M. Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest 105 (2000) 143-150
39. Adair-Kirk T.L., Atkinson J.J., Broekelmann T.J., Doi M., Tryggvason K., Miner J.H., et al. A site on laminin alpha 5, AQARSAASKVKVSMKF, induces inflammatory cell production of matrix metalloproteinase-9 and chemotaxis. J Immunol 171 (2003) 398-406